OBIO Announces 2018 CAAP® Cohort with 12 High Potential Health Science Companies

CAAP Logo.png

OBIO is proud to announce its 2018 Capital Access Advisory Program (CAAP®) and the 12 high-potential health science companies in this year’s cohort. Now in its sixth year, this year’s OBIO CAAP companies will work with OBIO and a vast network of expert advisors over the next year to achieve key goals and objectives which will position them for successful financing.  OBIO CAAP companies are advancing and accelerating the development and commercialization of therapeutics, diagnostics, medical devices and digital health products and services to benefit Ontario and global human health.

OBIO CAAP is a unique program for high-potential health science companies in Ontario. They receive personalized coaching, access to a global network of expert advisors, and strategic investor introductions that will ultimately drive fundraising success and lead to business and job growth.
— Gail Garland, OBIO President and CEO
“I highly encourage any health science entrepreneur to engage with OBIO as early as possible. During OBIO CAAP, the guidance and advice given to us was superb! The OBIO team understand and have the appropriate experience to guide life sciences companies effectively. During the OBIO CAAP year, we were provided with solid feedback on the content of our investor collaterals and strategy. There was great support and willingness to dig deep into the science, competitors, regulatory space, and truly refine our story. In summary, OBIO CAAP helped us get to a point of top investor readiness for our next round of financing.”
— Anton Neschadim, CEO of Immunobiochem, a 2017 OBIO CAAP company

To find out more about CAAP and this year's cohort of 11 high potential companies, please read the full press release here or download a PDF copy.

2018 OBIO CAAP Companies

Adapsyn Bioscience

Adapsyn Bioscience has developed a bioinformatics platform that uses machine learning and microbial genomic and metabolomic data to identify novel natural products that can be developed as biomarkers or therapeutics.

Braze Mobility

Braze Mobility offers an after-market product for powered wheelchairs that increases safety by preventing collisions and offering feedback to the driver, while maximizing driver autonomy and freedom.

Bright Angel Therapeutics

Bright Angel Therapeutics is developing a novel antifungal drug platform that targets antifungal drug resistance to transform existing antifungals from ineffective to highly efficacious against all leading fungal pathogens.

Elucid Labs

Elucid is building the world’s first AI dermatology assistant (AIDA™) system as clinical decision support for early detection and non-invasive diagnosis of skin cancer and skin diseases.


HelpWear has developed HeartWatch, a clinical grade contactless ECG monitor that will contact EMS after detecting heart attacks.


LifeShield has developed a transparent antibacterial adhesive film for touch screens in hospitals and other settings which inhibits the spread of infections.


MDDT has developed TremorTek, a theranostic device to guide neurologists in treating Parkinson tremors using botulinum toxin.


MediSeen is a home health care practice management platform that enables physicians and allied care providers to grow their house call practice.

Next Healthcare

Ontario based Next Healthcare Technologies has built CareCDS, a real-time information gathering platform for healthcare and pharma industry.


Polumiros has developed ReFilx, a polymeric filler that provides breast cancer patients a cosmetically superior and minimally-invasive solution for the restoration of tissue defects following lumpectomy.

Rna Diagnostics

Rna Diagnostics is transforming cancer treatment with their RNA Disruption Assay, a treatment response monitoring technology that allows oncologist to know early on if cancer treatment is efficacious or should be stopped.


Steadiwear has created a lightweight battery-free glove, called Steadiglove, that reduces hand tremors in Essential Tremor and Parkinson’s Disease allowing patients to do their daily activities with less frustration and more independence.